

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62298 A2

(51) International Patent Classification⁷: **A61K 47/48**,
C07K 14/525, 14/54, 14/57, A61P 35/00

(21) International Application Number: **PCT/IB01/00382**

(22) International Filing Date: 22 February 2001 (22.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/184,767 24 February 2000 (24.02.2000) US
60/257,192 21 December 2000 (21.12.2000) US

(71) Applicant (for all designated States except US): **PHILO-
GEN S.R.L.** [IT/IT]; La Lizza-7, I-53100 Siena (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZARDI, Luciano** [IT/IT]; IST-Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10, I-16132 Genoa (IT). **NERI, Dario** [IT/CH]; Department of Applied Biosciences, Swiss Federal Institute of Technology Zurich, Irchel Y36 M14, Winterthurerstrasse 190, CH-8057 Zurich (CH). **CARNEMOLLA, Barbara** [IT/IT]; Via Umberto Terracini, 134/2, I-16166 Genoa (IT). **NILSSON, Fredrik** [CH/CH]; Department of Applied Biosciences, Swiss Federal Institute of Technology Zurich, Irchel Y36 M14, Winterthurerstrasse 190, CH-8057 Zurich (CH). **TARLI, Lorenzo** [IT/CH]; Department of Applied Biosciences, Swiss Federal Institute of Technology Zurich, Irchel

Y36 M14, Winterthurerstrasse 190, CH-8057 Zurich (CH). **BORSI, Laura** [IT/IT]; Via Eugenia Ravasco, 4/2, I-16128 Genoa (IT). **HALIN, Cornelia** [CH/CH]; Department of Applied Biosciences, Swiss Federal Institute of Technology Zurich, Irchel Y36 M14, Winterthurerstrasse 190, CH-8057 Zurich (CH).

(74) Agents: **WALTON, Seán, M. et al.**; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/62298 A2

(54) Title: **COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS IN PATHOLOGICAL LESIONS**

(57) Abstract: Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12(IL-12), Interferon- γ (IFN- γ), Tumor Necrosis Factor α (TNF α) or Tissue Factor protein (which may be truncated).

COMPOSITIONS AND METHODS FOR TREATMENT
OF ANGIOGENESIS IN PATHOLOGICAL LESIONS

The present invention relates to treatment of lesions of
5 pathological angiogenesis, especially tumors, rheumatoid
arthritis, diabetic retinopathy, age-related macular
degeneration, and angiomas. Aspects of the present invention
employ a conjugate or fusion of a molecule that exerts a
biocidal or cytotoxic effect on target cells in the lesions
10 and an antibody directed against an extracellular matrix
component which is present in such lesions. In preferred
embodiments, the antibody is directed against fibronectin ED-
B. Preferred embodiments of the biocidal or cytotoxic
molecule include interleukin-2 (IL-2), doxorubicin,
15 interleukin-12 (IL-12), Interferon- γ (IFN- γ), Tumor Necrosis
Factor α (TNF α) also, especially with the L19 antibody (see
below), tissue factor (preferably truncated). By targeting
bioactive molecules to an extracellular matrix component,
killing of target cells may be achieved.

20 Tumors cannot grow beyond a certain mass without the
formation of new blood vessels (angiogenesis), and a
correlation between microvessel density and tumor
invasiveness has been reported for a number of tumors (1).
25 Molecules capable of selectively targeting markers of
angiogenesis create clinical opportunities for the diagnosis
and therapy of tumors and other diseases characterized by
vascular proliferation, such as rheumatoid arthritis,
diabetic retinopathy and age-related macular degeneration (2-
30 8).

The ED-B domain of fibronectin, a sequence of 91 amino acids
identical in mice, rats and humans, which is inserted by

alternative splicing into the fibronectin molecule, specifically accumulates around neovascular structures and represents a target for molecular intervention (9-11). Using a human recombinant antibody (L19) to the ED-B domain the
5 possibility of *in vivo* neovasculature targeting has been demonstrated in different tumor models (12,13).

The present invention is based on the inventors' experimental work employing an antibody directed against the ED-B domain
10 of fibronectin, found in angiogenesis in pathological lesions such as tumors, conjugated with molecules that exert biocidal or cytotoxic effects on target cells. Some such molecules may interact with a membrane-bound receptor on the target cell or perturb the electrochemical potential of the cell
15 membrane. Exemplary molecules demonstrated experimentally herein include interleukin-2 (IL-2), tissue factor, doxorubicin, interleukin-12 (IL-12), Interferon- γ (IFN- γ) and Tumor Necrosis Factor α (TNF α).

20 Interleukin-2 (IL-2), a four α helix bundle cytokine produced by T helper 1 cells, plays an essential role in the activation phases of both specific and natural immune responses (14). IL-2 promotes proliferation and differentiation of activated T and B lymphocytes and of
25 natural killer (NK) cells, and induces cytotoxic T cell (CTL) activity and NK/lymphokine activated killer (LAK) antitumor cytotoxicity. IL-2 has been used in immunotherapy approaches of several human tumors (15). Administration of recombinant IL-2 (rIL2) alone or in combination with adoptively
30 transferred lymphoid cells has resulted in the regression of established tumors in both animal models and patients. However, its *in vivo* therapeutic efficacy is limited by its rapid clearance and, at high doses, by a severe toxicity

mainly related to a vascular leak syndrome (16). Delivery of IL-2 to the tumor site by means of an antibody directed against a cell-surface tumor marker may allow achievement of active local concentrations of IL-2, as well as reducing
5 toxicities associated to systemic administration (17).

In certain embodiments, the present invention diverges in a novel and unobvious way from the referenced prior art by conjugating IL-2 to an antibody directed to an extracellular
10 matrix component, which component is present in angiogenesis in pathological lesions. As noted, in the prior art attempts to employ IL-2 in treatment of tumors by delivery using an antibody, the antibody has been directed against a cell-surface tumor marker. However, tumor cells present a great
15 heterogeneity in expression of cell surface tumor markers, and may be down-regulated during therapies.

The presence of IL-2 bound at a tumor cell surface results in activation and/or targeting of effector cells of the immune
20 system, either CD8⁺ cytotoxic T cells or natural killer (NK) cells, and in the induction of an efficient anti-tumor immune response. T or NK cells receive one signal through receptor(s) (for instance T-cell receptor for T cells) specifically recognizing appropriate ligands at the tumor
25 cell surface, and a second signal through IL-2 receptor chains by IL-2, also localized at the tumor cell surface (Lode et al., 1999, *PNAS USA*, 96: 8591-8596 and references therein).

30 Differently, in the experiments described in more detail below, the inventors constructed and expressed in mammalian cells an antibody-IL2 fusion protein, the antibody (L19, of which the sequence is disclosed in Pini et al. (1998) *J. Biol. Chem.* 273: 21769-21776) being directed against a

component of the extracellular matrix present in angiogenesis in pathological lesions (in particular fibronectin ED-B). *In vivo* biodistribution experiments in tumor bearing mice demonstrated accumulation of the fusion protein around new forming tumor blood vessels. The fusion protein was tested in therapeutic experiments in tumor bearing animals and surprisingly found to induce an antitumor effect and to be significantly more active in reducing tumor growth than an equimolar mixture of L19 and IL-2.

10

Tissue factor is a component of the blood coagulation cascade, normally present in a membrane-anchored form in the adventitia of blood vessels and therefore not accessible to other components of the blood coagulation cascade. When blood vessels are damaged (e.g. in a wound), tissue factor becomes accessible and, upon binding to Factor VIIa, starts a series of biochemical processes which result in blood clot formation. The truncated form of TF (residues 1-219) is significantly less active in promoting blood coagulation and can therefore be injected systemically either alone, or bound to a monoclonal antibody.

Thorpe and colleagues have demonstrated in an artificial system the principle of selective intraluminal blood coagulation in tumoral blood vessels, resulting in tumor infarction and subsequent tumor cell death (X. Huang et al. (1997) *Science*, 275, 547-550). The authors subcutaneously implanted tumor cells, engineered to secrete interferon gamma and therefore to up-regulate MHC-II expression on the luminal surface of surrounding (tumoral) blood vessels. By doing so, they created an artificial marker of angiogenesis which could be used for molecular intervention. The authors then injected these tumor-bearing mice with bispecific antibodies, capable of simultaneous binding to a truncated form of tissue factor

(TF) and to MHC-II, precomplexed with TF. This macromolecular complex (Acoaguligand®) mediated the rapid tumor infarction and complete remission in some of the tumor-bearing mice treated.

5

In a second experimental system, Thorpe and colleagues used as therapeutic agent a monoclonal antibody specific for the vascular cell adhesion molecule-1 (VCAM-1), chemically cross-linked to TF (Ran et al. (1998) *Cancer Res.*, 58, 4646-4653).

10 As tumor model, the authors chose SCID mice bearing a human L540 Hodgkin's tumors. A 50% reduction in tumor growth rate was observed. Based on their observations, the authors concluded that the selective thrombotic action on tumor and not normal cells resulted from a requirement for coincident
15 expression of the target molecule VCAM-1 and PS on the tumor endothelial cell surface. This provided expectation that the selective thrombotic action would occur only if coaguligands are delivered to the luminal side of new blood vessels and only if these blood vessels display PS on their luminal side.

20

US patents US-A-6,004,555 and US-A-5,877,289 describe work by Thorpe with tissue factor.

The present inventors have now found that tissue factor
25 delivered to the extracellular matrix of pathological lesions, e.g. tumors, is surprisingly able to mediate a biocidal effect (e.g. on tumor cells), specifically infarction, especially when fused to an L19 antibody molecule (see below). In accordance with the present invention,
30 tissue factor (preferably truncated as is known in the art) is provided as a conjugate or fusion with a specific binding member directed to a component of the extracellular matrix found in lesions of pathological angiogenesis, e.g. fibronectin ED-B or tenascin-C.

Doxorubicin (doxo) is one of the most effective anti-cancer drugs used to treat cancer and one of a few chemotherapeutic agents known to have antiangiogenic activity. However,
5 doxorubicin has no cytotoxic activity when bound to antibodies directed against tumor-associated markers on the cell membrane which do not internalise (Chari (1998) *Advanced Drug Delivery* 31, 89-104). Conjugates of doxorubicin and a rapidly internalising antibody directed against tumour-
10 associated markers expressed on the surface of tumour cells have been shown to have an anti-tumour effect (R.V.J. Chari, 1998).

The present inventors have, differently, targeted doxorubicin
15 to the extracellular matrix of lesions, e.g. tumors, by conjugation with a specific binding member directed against a component of the extracellular matrix. In a preferred embodiment demonstrated experimentally herein, the inventors conjugated doxorubicin to an antibody fragment directed
20 against fibronectin ED-B by means of a cleavable linker, allowing for slow release of the doxorubicin. The experiments demonstrate a therapeutic effect. Unlike other approaches, this cleavage occurs in the extracellular milieu, and does not rely on internalisation and/or proteolytic
25 cleavage.

IL-12 is a heterodimeric protein composed of a 40 kD (p40) subunit and a 35 kD (p35) subunit. IL-12 is produced by macrophages and B lymphocytes and has been shown to have
30 multiple effects on T cells and natural killer (NK) cells. Some of these IL-12 activities include the induction of interferon gamma in resting and activated T and NK cells, the enhancement of cytotoxic activity of NK and T cells, and the stimulation of resting T cell proliferation In the presence

of a comitogen. Current evidence indicates that IL-12 is a key mediator of cellular immunity. Based on its activity, it has been suggested that IL-12 may have therapeutic potential as a vaccine adjuvant that promotes cellular-immunity and as
5 an anti-viral and anti-tumor agent. In fact, IL-12 is currently being evaluated as an anti-cancer drug in Phase I/II clinical trails (Genetics Institute, Cambridge MA). However, in the phase II clinical study administration of recombinant human IL-12 (rhIL-12) resulted in severe toxicity
10 (Atkins et. Al, 1995). This has, so far, hampered its further development. In this context, it appears that developing strategies for locally constricted delivery of the cytokine to the tumor could reduce the problems related to toxicity in clinical applications.

15 Single peptide chain p40-p35 fusions (Lieschke et. al, 1997) retain specific *in vivo* activity, comparable to that of native and recombinant IL-12. The present inventors have constructed a single polypeptide fusion protein of the murine
20 p35-p40 genes with the antibody L19, directed against the ED-B domain of fibronectin, a component of the extracellular matrix and a marker of angiogenesis. By an *in vitro* assay (T cell proliferation assay) it was demonstrated that the IL-12-L19 fusion protein retained IL-12 activity comparable to
25 commercially available IL-12. Furthermore, *in vivo* biodistribution experiments in mice proved accumulation of the fusion protein in tumors.

IL-12 has been supposed to act at the cell surface level.
30 Thus, it was not predictable that depositing and enriching it in the tumoral extracellular matrix (ECM) would have any effect on the rate of tumor growth. In therapeutic experiments, however, the fusion protein was found to induce anti-tumor effects comparable to the ones obtained with the

L19-IL2 fusion protein by significantly reducing tumor growth in tumor bearing mice.

Interferon gamma (IFN- γ) is a pleiotropic cytokine that plays a central role in promoting innate and adaptive mechanisms of host defence. It is now well recognised that IFN- γ , a non-covalently associated homodimeric cytokine, exerts its biologic effects by interacting with an IFN- γ receptor that is ubiquitously expressed on nearly all cells. Functionally active IFN- γ receptors consist of two distinct subunits: a 90-kDa receptor alpha chain and a 62-kDa receptor beta chain. The physiologic role of IFN- γ in promoting host resistance to infectious organisms is unequivocal (Newport et al. (1996) *New Engl. J. Med.*, 335, 1941-1949; Jouanguy et al. (1996) *New Engl. J. Med.*, 335, 1956-1961).

In contrast, the role that IFN- γ plays in the development of host anti-tumor responses is less well established. IFN- γ plays a critical role in promoting rejection of transplantable tumors. Furthermore, endogenously produced IFN- γ forms the basis of a tumor surveillance system that controls development of both chemically induced and spontaneously arising tumors in mice.

Considering that production of IFN- γ makes a tumor immunogenic, it is tempting to speculate that decorating a tumor with IFN- γ (for example, by means of IFN- γ -antibody fusion proteins) may lead to an anti-tumor response. Systemically administered unconjugated IFN- γ has been studied in multi-centre clinical trials in patients with cancer, with very modest response rates. However, recent indication of clinical usefulness of intraperitoneal applications of IFN- γ

in patients with ovarian cancer has become available from a Phase III clinical trial (Windbichler et al. (2000) *Br. J. Cancer*, 82, 1138-1144).

5 The present inventors have found that when targeting the L19-interleukin-12 fusion protein to tumor vasculature in tumor bearing mice, they have observed increased levels of IFN- γ in the blood. In contrast, no elevated levels of IFN- γ could be detected with a non-targeted scFv-interleukin-12 fusion
10 protein.

Tumor Necrosis Factor α (TNF α) is a cytokine produced by many cell types, mainly activated monocytes and macrophages. It is expressed as a 26 kDa integral transmembrane precursor
15 protein from which a mature protein of approximately 17kDa is released by proteolytic cleavage. The soluble bioactive TNF α is a homotrimer that interacts with two different cell surface receptors (Tartaglia L.A., et al *J. Biol. Chem.*, 268: 18542-18548, 1993) p55TNFR (50-60 kDa) and p75TNFR (75-80
20 kDa). p75TNFR is species-specific; in fact, human TNF α does not bind to this mouse receptor.

TNF α can induce hemorrhagic necrosis of transplanted solid tumors, *in vivo* (Carswell E.A., et al, *Proc. Natl. Acad. Sci. USA*, 72: 3666-3670, 1975), and can exert cytotoxic activity
25 *in vitro* against some tumor cell lines (Helson L., et al, *Nature*, 258: 731-732. 1975).

The anti-tumor efficiency of TNF α in some animal models
30 fostered hopes of its possible use as a therapeutic agent in human cancer. Clinical trials performed to demonstrate the anti-tumor efficacy of TNF α , however, showed that systemically administered therapeutically effective doses

were accompanied by unacceptably high levels of systemic toxicity, hypotension being the most common dose-limiting toxic effect. Moreover, TNF α has a very rapid clearance from the bloodstream (plasma half-life generally less than 30 minutes) (Blick M.m et al. *Cancer Res.*, 47: 2989, 1987), which decreases the hematic concentration under therapeutic levels, very rapidly. Good clinical results have been achieved in humans only in loco-regional treatments of non disseminated tumors (e.g., isolated-limb-perfusion for sarcoma and melanoma). (Franker D. L., et al, *Important Adv. Oncol.* 179-192, 1994.)

The anti-tumor activity of TNF α in many animal models seems to be due to a combination of a direct toxic effect (in combination with tumor-derived factors that synergise with TNF α) on endothelial cells of the growing tumor vasculature (Clauss M., et al. *J. Biol Chem.*, 265:7078-7083, 1990a), as well as to alterations of the hemostatic properties of proliferating endothelial cells in tumor angiogenesis (Clauss., et al *J. Exp. Med.*, 172:1535-1545, 1990b). There is also evidence of a direct cytotoxic effect on tumor cells. Indirect (host-mediated) effects of TNF α , such as the induction of T cell-dependent immunity, can contribute to tumor regression on animal models (Palladino Jr. M.A., et al. *J Immunol.*, 138:4023-4032, 1987).

In the experiments described below, the inventors constructed and expressed on mammalian cells an antibody-murine TNF α (mTNF α) fusion protein, the antibody L19 being directed against a component of the ECM present in angiogenesis in pathological lesions (in particular B-FN). *In vivo* biodistribution experiments in tumor-bearing mice demonstrated accumulation of the fusion protein around new forming tumor blood vessels. The fusion protein was tested

in therapeutic experiments in tumor bearing animals and surprisingly was found to induce an anti-tumor effect and to be active in reducing tumor growth.

5 *Brief Description of the Figures*


Figure 1 shows a schematic representation of the scFv L19-IL2 cDNA construct. scFv-L19 and IL2 cDNA were genetically fused with a DNA linker (—) encoding for 15 amino acids
10 (SSSSG)₃ and cloned into the pcDNA3 mammalian expression vector using the HindIII and BamHI restriction sites. The hatched box represents the CMV promoter sequence, the filled box the genomic sequence of the signal secretion leader peptide ( intron inside of the genomic sequence) and
15 white boxes the VH or VL of scFV-L19 and IL2 sequence. T7, BC666, BC679 and BC695 are primers used in the PCR amplifications described in Materials and Methods.

Figure 2 shows biological activity of the IL2 portion of the
20 fusion protein (○) and of IL2 contained in a mixture of equimolar concentrations of L19 and IL2 (●) measured by CTLL cell proliferation.

Figure 3 shows results of a biodistribution analysis
25 performed in mice bearing a subcutaneously-implanted murine F9 teratocarcinoma, injected intravenously with radioiodinated scFv(L19)-TF.

Figure 4 is a plot (versus time) of the volume of F9 murine
30 teratocarcinoma tumors subcutaneously implanted in mice, which have been injected intravenously with 3 doses of either scFv(L19)-TF or scFv(D1.3)-TF. The first injection (indicated by an arrow) was performed when tumors were small. Standard errors are indicated.

Figure 5 is a plot (versus time) of the volume of C51 murine carcinoma tumors subcutaneously implanted in mice, which have been injected intravenously with 3 doses of either scFv(L19)-TF or scFv(D1.3)-TF. The first injection (indicated by an arrow) was performed when tumors were small. Standard errors are indicated.

Figure 6 is a plot (versus time) of the volume of C51 murine carcinoma tumors subcutaneously implanted in mice, which have been injected intravenously with 1 dose of either scFv(L19)-TF (20 µg), scFv(D1.3)-TF (20 µg) or phosphate buffered saline. The injection (indicated by an arrow) was performed when tumors were > 1 gram. Standard errors are indicated.

Figure 7 is a plot (versus time) of the volume of FE8 ras-transformed fibroblast tumors subcutaneously implanted in mice, which have been injected intravenously with with 1 dose of either scFv(L19)-TF (20 µg), scFv(D1.3)-TF (20 µg) or phosphate buffered saline. The injection (indicated by an arrow) was performed when tumors were > 1 gram. Standard errors are indicated.

Figure 8 illustrates the kinetic of doxorubicin release from scFv(L19)-doxorubicin conjugates, analysed by HPLC.

Figure 9 illustrates the toxicity towards C51 murine carcinoma cells, mediated by doxorubicin released from a scFv(L19)-doxorubicin conjugate.

Figure 10 is a plot (versus time) of the volume of F9 murine teratocarcinoma tumors subcutaneously implanted in mice, which have been injected intravenously with 5 doses of either scFv(L19)-doxorubicin [18 µg/injection] or phosphate buffered

saline. The first injection (indicated by an arrow) was performed when tumors were small. Standard errors are indicated.

Figure 11 shows a schematic representation of the IL12-L19
5 cDNA construct. The p35 and p40 subunits were genetically
fused with DNA linker encoding for 15 amino acids (GGGGS)₃ and
further fused to the L19 sequence by another linker of 6
amino acids (GSADGG). The entire fusion protein encoding
sequence was cloned into the pcDNA3.1 mammalian expression
10 vector using the EcoRI and NotI restriction sites, as
described below. *sp40backEco*, *linkp40for*, *linkp35back*,
linkp35for, *linkL19back*, and *FlagforNot* are primers used in
the PCR amplification described in the experimental
description below.

15
Figure 12 shows the biological activity of IL12 moiety of the
fusion protein in comparison with commercially available
recombinant murine IL12 as measured in a T cell proliferation
assay.

20
Figure 13 shows the results of a biodistribution analysis
performed in mice bearing subcutaneously implanted F9
teratocarcinoma which were injected intravenously with
radioiodinated IL12-L19 fusion protein.

25
Figure 14 shows a plot (versus time in hours) of the volume
of C51 colon carcinoma tumors (in mm³) subcutaneously
implanted in mice which have been injected (indicated by
arrows) with either PBS or 2.5µg of IL12-L19 fusion protein
30 every 48 hours. Injections were started when tumors were
small ($\approx 30\text{mm}^3$).

Figure 15 shows a plot (versus time in hours) of the volume
of C51 colon carcinoma tumors (in mm³) subcutaneously

implanted in mice which have been injected (indicated by arrows) with either PBS or 10µg of IL12-L19 fusion protein every 48 hours.

5 Figure 16 shows a plot (versus time) of the volume of C51 colon carcinoma tumors subcutaneously implanted in mice which have been injected (indicated by arrows) with PBS, IL12-HyHEL10 fusion protein (2.5 µg/injection) or IL12-L19 fusion protein (2.5 µg/injection) every 48 hours.

10

Figure 17 illustrates a construct encoding a fusion protein wherein a monomer of IFN-γ is fused at the C-terminal extremity of scFv(L19). IFN-γ causes homodimerisation of the fusion protein.

15

Figure 18 illustrates a construct encoding a fusion protein wherein a single-chain homodimeric IFN-γ is fused at the C-terminal extremity of scFv(L19). In solution, the protein dimerises non-covalently, giving rise to a protein of MW =

20 125 kDa.

Figure 19 illustrates vector pIS14 that encodes a fusion protein comprising the L19 scFv and monomeric IFN-γ.

25 Figure 20 illustrates vector pIS16 that encodes a fusion protein comprising the L19 scFv and dimeric IFN-γ.

Figure 21 shows a schematic representation of the scFv L19-mTNFα cDNA construct. scFv L19 and mTNFα cDNA were
30 genetically fused with a DNA linker encoding for 15 amino acids (SSSSG); and cloned into the pcDNA mammalian expression vector using the HindIII and Not I restriction sites. The hatched box represents the CMV promoter sequence, the filled

box the genomic sequence of the signal secretion leader peptide (--- intron inside of the genomic sequence) and white boxes the VH or VL of scFV-L19 and mTNF α sequence. T7, BC679, BC742 and BC749 and primers used in the PCR
5 amplifications described in Materials and Methods.

Figure 22 shows the biological activity of the mTNF α portion of the fusion protein (■) and of recombinant mTNF α (▲) measured by cytotoxicity assay on mouse L-M fibroblasts (see
10 Materials and Methods in Example 7).

Figure 22 is a plot (versus time) of the volume of C51 murine colon carcinoma subcutaneously implanted in Balb/C mice which were intravenously injected with either scFV(L19)-mTNF α or
15 PBS (as negative control). The injection is indicated by the arrow and performed when tumors were approximately 100-200mm³. Standard errors are indicated.

All documents cited herein are incorporated by reference.
20

The present invention provides for treatment of lesions of pathological angiogenesis.

25 In one aspect the invention provides a method of treating angiogenesis in pathological lesions, the method comprising administering a conjugate of (i) a molecule which exerts a biocidal or cytotoxic effect on target cells by cellular interaction and (ii) a specific binding member specific for
30 an extracellular matrix component which is present in angiogenesis in pathological lesions.

In another aspect, the invention provides the use of a conjugate of (i) a molecule which exerts a biocidal or

cytotoxic effect on target cells by cellular interaction and
(ii) a specific binding member specific for an extracellular
matrix component which is present in angiogenesis in
pathological lesions, in the manufacture of a medicament for
5 treatment of pathological angiogenesis.

In a further aspect the invention provides a conjugate of (i)
a molecule which exerts a biocidal or cytotoxic effect on
target cells by cellular interaction and (ii) a specific
10 binding member specific for an extracellular matrix component
which is present in angiogenesis in pathological lesions, for
use in a method of treatment of the human or animal body by
therapy. Such treatment may be of pathological lesions
comprising angiogenesis.

15

A still further aspect of the invention provides a conjugate
of (i) a molecule which exerts a biocidal or cytotoxic effect
on target cells by cellular interaction and (ii) a specific
binding member specific for an extracellular matrix component
20 which is present in angiogenesis in pathological lesions.
Such a conjugate preferably comprises a fusion protein
comprising the biocidal or cytotoxic molecule and a said
specific binding member, or, where the specific binding
member is two-chain or multi-chain, a fusion protein
25 comprising the biocidal or cytotoxic molecule and a
polypeptide chain component of said specific binding member.

Preferably the specific binding member is a single-chain
polypeptide, e.g. a single-chain antibody molecule, such as
scFv. Thus a further aspect of the present invention
30 provides a fusion protein comprising the biocidal or
cytotoxic molecule and a single-chain Fv antibody molecule
specific for an extracellular matrix component which is
present in lesions comprising angiogenesis, especially a
tumor-associated extracellular matrix component. As

discussed, in a preferred embodiment the component allowing for discriminatory targeting of extracellular matrix of pathological lesions compared with normal is fibronectin ED-B. In another preferred embodiment the component is the C domain of tenascin-C (Carnemolla et al. (1999) *Am. J. Pathol.*, 154, 1345-1352)).

The biocidal or cytotoxic molecule that exerts its effect on target cells by cellular interaction, may interact directly with the target cells, may interact with a membrane-bound receptor on the target cell or perturb the electrochemical potential of the cell membrane. Molecules which interact with a membrane-bound receptor include chemokines, cytokines and hormones. Compounds which perturb the electrochemical potential of the cell membrane include hemolysin, ionophores, drugs acting on ion channels. In exemplary preferred embodiments the molecule is interleukin-2, tissue factor (preferably truncated) or doxorubicin. Other embodiments may employ interleukin 12, interferon-gamma, IP-10 and Tumor Necrosis Factor- α (TNF- α).

As discussed further below, the specific binding member is preferably an antibody or comprises an antibody antigen-binding site. Conveniently, the specific binding member may be a single-chain polypeptide, such as a single-chain antibody. This allows for convenient production of a fusion protein comprising single-chain antibody and the biocidal or cytotoxic molecule (e.g. interleukin-2 or tissue factor). In other embodiments, an antibody antigen-binding site is provided by means of association of an antibody VH domain and an antibody VL domain in separate polypeptides, e.g. in a complete antibody or in an antibody fragment such as Fab or diabody. Where the specific binding member is a two-chain or

multi-chain molecule (e.g. Fab or whole antibody, respectively), the biocidal or cytotoxic molecule may be conjugated as a fusion polypeptide with one or more polypeptide chains in the specific binding member.

5

The specific binding member may be specific for fibronectin ED-B, or the C domain of tenascin-C.

10 An antibody antigen-binding site used in a specific binding member in accordance with the present invention may include the VH and/or VL domains of the antibody L19 or an antibody that competes with L19 for binding to ED-B. The L19 VH and L19 VL domain sequences are disclosed in Pini et al. (1998) *J. Biol. Chem.* 273: 21769-21776.

15

Other non-antibody specific binding members which may be conjugated with IL-2, TF, doxo, IL-12, IFN- γ or TNF- α or other biocidal or cytotoxic molecules and used in accordance with the present invention include peptides, aptamers and
20 small organic molecules able to interact with a component of the ECM associated with pathological lesions.

As noted, preferably the specific binding member is conjugated with the biocidal or cytotoxic molecule by means
25 of a peptide bond, i.e. within a fusion polypeptide comprising said molecule and the specific binding member or a polypeptide chain component thereof. See Taniguchi et al. (1983) *Nature* 302, 305-310; Maeda et al. (1983) *Biochem. Biophys. Res. Comm.* 115: 1040-1047; Devos et al. (1983) *Nucl. Acids Res.* 11: 4307-4323 for IL-2 sequence information useful
30 in preparation of a fusion polypeptide comprising IL-2. Sequence information for truncated tissue factor is provided by Scarpati et al. (1987) *Biochemistry* 26: 5234-5238, and Ruf

et al. (1991) *J. Biol. Chem.* 226: 15719-15725. Other means for conjugation include chemical conjugation, especially cross-linking using a bifunctional reagent (e.g. employing ADOUBLE-REAGENTS™@ Cross-linking Reagents Selection Guide, 5 Pierce).

Where slow release is desirable, e.g. where the biocidal or cytotoxic molecule is doxorubicin or other molecule which perturbs the electrochemical potential of the cell membrane, chemical conjugation may be by means of formation of a Schiff 10 base (imine) between a primary amino group of the specific binding member (a polypeptide such as an antibody or antibody fragment) and an oxidised sugar moiety (daunosamine) of the biocidal or cytotoxic molecule such as doxorubicin.

15 The lesion treated may be a tumor, including without limitation any one or more of the following: melanoma, neuroblastoma, colorectal carcinoma, renal carcinoma, lung, carcinoma, lung metastasis, breast carcinoma, high-grade astrocytoma (grade III, grade IV), meningioma, angioma.

20

The lesion may be ocular, e.g. arising from age-related macular degeneration, in which angiogenesis arises from choroidal vessels.

25 *Specific binding member*

This describes a member of a pair of molecules which have binding specificity for one another. The members of a specific binding pair may be naturally derived or wholly or partially synthetically produced. One member of the pair of 30 molecules has an area on its surface, or a cavity, which specifically binds to and is therefore complementary to a particular spatial and polar organisation of the other member of the pair of molecules. Thus the members of the pair have the property of binding specifically to each other.

Antibody

This describes an immunoglobulin whether natural or partly or wholly synthetically produced. The term also covers any
5 polypeptide or protein having a binding domain which is, or is substantially homologous to, an antibody antigen-binding domain. These can be derived from natural sources, or they may be partly or wholly synthetically produced. Examples of antibodies are the immunoglobulin isotypes and their isotypic
10 subclasses; fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd; and diabodies.

It is possible to take monoclonal and other antibodies and use techniques of recombinant DNA technology to produce other
15 antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus
20 framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB 2188638A or EP-A-239400. A hybridoma or other cell producing an antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.

25

As antibodies can be modified in a number of ways, the term "antibody" should be construed as covering any specific binding member having an antibody antigen-binding domain binding domain with the required specificity. Thus, this
30 term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or wholly or partially synthetic. Chimeric molecules comprising an immunoglobulin binding domain, or

equivalent, fused to another polypeptide are therefore included. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.

- 5 It has been shown that fragments of a whole antibody can perform the function of binding antigens. Examples of binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CH1 domains; (ii) the Fd fragment consisting of the VH and CH1 domains; (iii) the Fv fragment consisting of
10 the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al., Nature 341, 544-546 (1989)) which consists of a VH domain; (v) isolated CDR regions; (vi) F(ab')₂ fragments, a bivalent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv), wherein
15 a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site (Bird et al, Science, **242**, 423-426, 1988; Huston et al, PNAS USA, **85**, 5879-5883, 1988); (viii) bispecific single chain Fv dimers (PCT/US92/09965) and (ix) "diabodies",
20 multivalent or multispecific fragments constructed by gene fusion (WO94/13804; P. Holliger et al, Proc. Natl. Acad. Sci. USA **90** 6444-6448, 1993). Fv, scFv or diabody molecules may be stabilised by the incorporation of disulphide bridges linking the VH and VL domains (Y. Reiter et al, Nature
25 Biotech, **14**, 1239-1245, 1996). Minibodies comprising a scFv joined to a CH3 domain may also be made (S. Hu et al, Cancer Res., **56**, 3055-3061, 1996).

Antigen binding domain

- 30 This describes the part of an antibody which comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antibody may only bind to a particular part of the antigen, which part is termed an epitope. An antigen binding domain may be

provided by one or more antibody variable domains (e.g. a so-called Fd antibody fragment consisting of a VH domain). Preferably, an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

Specific

This may be used to refer to the situation in which one member of a specific binding pair will not show any significant binding to molecules other than its specific binding partner(s). The term is also applicable where e.g. an antigen binding domain is specific for a particular epitope which is carried by a number of antigens, in which case the specific binding member carrying the antigen binding domain will be able to bind to the various antigens carrying the epitope.

Comprise

This is generally used in the sense of include, that is to say permitting the presence of one or more features or components.

Isolated

This refers to the state in which specific binding members of the invention, or nucleic acid encoding such binding members, will generally be employed in accordance with the present invention. Members and nucleic acid will be free or substantially free of material with which they are naturally associated such as other polypeptides or nucleic acids with which they are found in their natural environment, or the environment in which they are prepared (e.g. cell culture) when such preparation is by recombinant DNA technology practiced *in vitro* or *in vivo*. Members and nucleic acid may be formulated with diluents or adjuvants and still for

practical purposes be isolated - for example the members will normally be mixed with gelatin or other carriers if used to coat microtitre plates for use in immunoassays, or will be mixed with pharmaceutically acceptable carriers or diluents when used in diagnosis or therapy. Specific binding members may be glycosylated, either naturally or by systems of heterologous eukaryotic cells (e.g. CHO or NS0 (ECACC 85110503) cells, or they may be (for example if produced by expression in a prokaryotic cell) unglycosylated.

10

As noted, where an antibody antigen-binding domain directed against fibronectin ED-B is to be employed in embodiments of the present invention, a preferred such domain comprises the L19 antibody VH and VL domains. Modified forms of one or other of these domains may be employed in further embodiments, e.g. the L19 VH or L19 VL domain in which 1, 2, 3, 4 or 5 amino acid substitutions have been made in a CDR, e.g. CDR3, and/or FR, which specific binding members retain ability to bind fibronectin ED-B. Such amino acid substitutions are generally "conservative", for instance substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. At certain positions non-conservative substitutions are allowable.

The present invention further extends to employing a specific binding member which competes with the L19 antibody for binding to fibronectin ED-B. Competition between binding members may be assayed easily *in vitro*, for example by tagging a specific reporter molecule to one binding member which can be detected in the presence of other untagged binding member(s), to enable identification of specific

30

binding members which bind the same epitope or an overlapping epitope.

In addition to antibody sequences, a specific binding member
5 employed in accordance with the present invention may
comprise other amino acids, e.g. forming a peptide or
polypeptide, such as a folded domain, or to impart to the
molecule another functional characteristic in addition to
ability to bind antigen. Specific binding members of the
10 invention may carry a detectable label.

In further aspects, the invention provides an isolated
nucleic acid which comprises a sequence encoding a specific
binding member as defined above (e.g. wherein the specific
15 binding member or a polypeptide chain component is provided
as a fusion polypeptide with the biocidal or cytotoxic
molecule), and methods of preparing specific binding members
of the invention which comprise expressing said nucleic acids
under conditions to bring about expression of said binding
20 member, and recovering the binding member.

The present invention also provides constructs in the form of
plasmids, vectors, transcription or expression cassettes
which comprise least one nucleic acid as above.

25

The present invention also provides a recombinant host cell
which comprises one or more constructs as above. A still
further aspect provides a method comprising introducing such
nucleic acid into a host cell. The introduction may employ
30 any available technique. For eukaryotic cells, suitable
techniques may include calcium phosphate transfection, DEAE-
Dextran, electroporation, liposome-mediated transfection and
transduction using retrovirus or other virus, e.g. vaccinia
or, for insect cells, baculovirus. For bacterial cells,

suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage.

- 5 The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression of the gene.

Expression may conveniently be achieved by culturing under
10 appropriate conditions recombinant host cells containing the nucleic acid. Following production by expression a specific binding member may be isolated and/or purified using any suitable technique, then used as appropriate.

- 15 In one embodiment, the nucleic acid of the invention is integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.

20

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, yeast and baculovirus systems. Mammalian cell lines available in the
25 art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, NSO mouse melanoma cells and many others. A common, preferred bacterial host is *E. coli*. The expression of antibodies and antibody fragments in prokaryotic cells such
30 as *E. coli* is well established in the art. For a review, see for example Plückthun, A. Bio/Technology 9: 545-551 (1991). Expression in eukaryotic cells in culture is also available to those skilled in the art as an option for production of a specific binding member, see for recent reviews, for example

Reff, M.E. (1993) Curr. Opinion Biotech. 4: 573-576; Trill
J.J. et al. (1995) Curr. Opinion Biotech 6: 553-560.

Suitable vectors can be chosen or constructed, containing
5 appropriate regulatory sequences, including promoter
sequences, terminator sequences, polyadenylation sequences,
enhancer sequences, marker genes and other sequences as
appropriate. Vectors may be plasmids, viral e.g. 'phage, or
phagemid, as appropriate. For further details see, for
10 example, *Molecular Cloning: a Laboratory Manual*: 2nd edition,
Sambrook et al., 1989, Cold Spring Harbor Laboratory Press.
Many known techniques and protocols for manipulation of
nucleic acid, for example in preparation of nucleic acid
constructs, mutagenesis, sequencing, introduction of DNA into
15 cells and gene expression, and analysis of proteins, are
described in detail in *Short Protocols in Molecular Biology*,
Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992.
The disclosures of Sambrook et al. and Ausubel et al. are
incorporated herein by reference.

20

The present invention also provides a method which comprises
using a construct as stated above in an expression system in
order to express a specific binding member or polypeptide as
above.

25

Specific binding members according to the invention may be
used in a method of treatment of the human or animal body,
such as a method of treatment (which may include prophylactic
treatment) of a disease or disorder in a human patient which
30 comprises administering to said patient an effective amount
of a specific binding member of the invention. Conditions
treatable in accordance with the present invention are
discussed elsewhere herein.

Accordingly, further aspects of the invention provide methods of treatment comprising administration of a specific binding member as provided, pharmaceutical compositions comprising such a specific binding member, and use of such a specific binding member in the manufacture of a medicament for administration, for example in a method of making a medicament or pharmaceutical composition comprising formulating the specific binding member with a pharmaceutically acceptable excipient.

10 In accordance with the present invention, compositions provided may be administered to individuals. Administration is preferably in a "therapeutically effective amount", this being sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors. Appropriate doses of antibody are well known in the art; see Ledermann J.A. et al. (1991) Int J. Cancer 47: 659-664; Bagshawe K.D. et al. (1991) Antibody, Immunoconjugates and Radiopharmaceuticals 4: 915-922.

25 A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Specific binding members of the present invention, including those comprising an antibody antigen-binding domain, may be administered to a patient in need of treatment via any suitable route, usually by injection into the bloodstream an/dor directly into the site to be treated, e.g. tumor. The precise dose will depend upon a number of factors, the route

of treatment, the size and location of the area to be treated (e.g. tumor), the precise nature of the antibody (e.g. whole antibody, scFv molecule), and the nature of any detectable label or other molecule attached to the antibody. A typical
5 antibody dose will be in the range 10-50 mg. This is a dose for a single treatment of an adult patient, which may be proportionally adjusted for children and infants, and also adjusted for other antibody formats in proportion to molecular weight. Treatments may be repeated at daily,
10 twice-weekly, weekly or monthly intervals, at the discretion of the physician.

Specific binding members of the present invention will usually be administered in the form of a pharmaceutical
15 composition, which may comprise at least one component in addition to the specific binding member.

Thus pharmaceutical compositions according to the present invention, and for use in accordance with the present
20 invention, may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The
25 precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. intravenous.

For intravenous, injection, or injection at the site of
30 affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such

as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

5

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. Other treatments may include the administration of suitable doses of pain relief drugs such as non-steroidal anti-inflammatory drugs (e.g. aspirin, paracetamol, ibuprofen or ketoprofen) or opiates such as morphine, or anti-emetics.

10

The present invention provides a method comprising causing or allowing binding of a specific binding member as provided herein to an extracellular matrix component which is present in angiogenesis in pathological lesions. As noted, such binding may take place *in vivo*, e.g. following administration of a specific binding member, or nucleic acid encoding a specific binding member.

15

Further aspects and embodiments of the present invention will be apparent to those skilled in the art given the present disclosure. Aspects and embodiments of the invention are illustrated by the following experimental section.

20

EXPERIMENTAL

EXAMPLE 1

30 CONSTRUCTION AND *IN VIVO* ANTI-Tumor ACTIVITY OF ANTIBODY-IL2 FUSION

MATERIALS AND METHODS

Construction and expression of L19-IL2 fusion protein

The L19-IL2 cDNA was constructed by fusion of a synthetic sequence coding for human IL2 to the 3' end of the sequence coding for the scFv L19. The schematic representation of L19-IL2 cDNA construct is shown in Figure 1. IL2 cDNA was
5 amplified by Polymerase Chain Reaction (PCR) using BC-666 and BC695 primers and, as template, the IL2 cDNA produced by reverse transcriptase-polymerase chain reaction (RT-PCR) starting from RNA of human phytohaemagglutinin (PHA)-
10 activated peripheral blood lymphocytes as described by Meazza et al. 1996 (18).

The forward BC666 primer
(sequence:ctcgaattctcttctcctcatcgggtagta
15 gctcttccggctcatcgtccagcggcgccacctacttcaagttctaca) contained the EcoRI restriction enzyme sequence, a 45 bp encoding for by a 15 amino acids linker (Ser₄-Gly)₃ and 21 bases of the mature human IL2 sequence.

20 The reverse BC-695 primer (sequence:
ctcggatccttatcaattcagatcct
cttctgagatgagtttttgttcagtcagtggtgagatgatgct) contained the myc sequence (13), two stop codons and the BamHI restriction enzyme sequence.

25 The scFvL19, which contained in its 5' end the genomic sequence of the signal secretion leader peptide as reported by Li et al. 1997 (19), was amplified by PCR using T7 primer on the vector pcDNA3.1 (Invitrogen, Groningen, The
30 Netherlands) and the BC 679 primer (sequence:
CTCGAATTCtttgatttccaccttggtccc) containing 21bp of the 3' end of L19 and the EcoRI restriction enzyme sequence.
The fused gene was sequenced, introduced into the vector pcDNA3.1 containing the Cytomegalovirus (CMV) promoter and

expressed in P3U1 cells in the presence of G418 (750 µg/ml, Calbiochem, San Diego, CA). Clones of G418-resistant cells were screened for the secretion of L19-IL2 fusion protein by ELISA using recombinant ED-B domain of human Fibronectin (FN) as antigen.

FN recombinant fragments, ELISA immunoassay and Purification of L19-IL2 fusion protein

Recombinant FN fragments containing the type III homology repeats 7B89 and ED-B were produced as described by Carnemolla et al. 1996 (20). ELISA immunoassay was performed as reported by Carnemolla et al. 1996 (20). The L19-IL2 fusion protein was purified from the conditioned medium of one positive clone using the recombinant human fibronectin fragment 7B89 conjugated to Sepharose, by affinity chromatography as reported by Carnemolla et al. 1996 (20). The size of the fusion protein was analyzed in reducing condition on SDS-PAGE and in native condition by FPLC gel filtration on a Superdex S-200 chromatography column (Amersham Pharmacia Biotech, Uppsala, Sweden).

IL2 bioassay

The IL2 activity of the L19-IL2 fusion protein was determined using the CTLL mouse cell line, which is known to proliferate in response to human IL2 as described by Meazza et al. 1996, (18). Serial dilutions of L19-IL2 fusion protein and of an equimolar mixture of L19 and recombinant human IL2 (Proleukin, Chiron) at concentrations from 1000 to 0.01 ng/ml were used in the CTLL-2 proliferation assay.

30

Animals and cell lines

Female athymic-nude mice (8-week-old nude/nude CD1 mice, females) were obtained from Harlan Italy (Correzzana, Milano, Italy). F9, a mouse embryonal carcinoma, mouse T

cells (CTLL-2) and mouse myeloma cells were purchased from ATCC (American Type Culture Collection, Rockville, MD, USA; N592, human Small Cell Lung Cancer (SCLC) cell line, was kindly provided by Dr. J.D. Minna (National Cancer Institute and Naval Hospital, Bethesda, Maryland); C51, a mouse colon adenocarcinoma cell line derived from BALB/c, was kindly provided by Dr. M.P. Colombo (21).

Biodistribution of L19-IL2 fusion protein

10 Purified L19-IL-2 was radiolabeled with iodine-¹²⁵ using the Iodogen method (22) (Pierce, Rockford, IL). The immunoreactive radiolabeled L19-IL-2 (more than 90%) was affinity purified on a 7B89/Sepharose chromatography column. Nude mice with subcutaneously implanted F9 murine
15 teratocarcinoma (20,23) were intravenously injected with about 10 µg (4 µCi) of protein in 100 µl saline solution. Three animals were used for each time point. Mice were sacrificed at 3, 6 and 24 hours after injection. The organs were weighed and the radioactivity was counted. All organs
20 and tumors were placed in fixative for histological analysis and microautoradiography. Targeting results of representative organs are expressed as percent of the injected dose per gram of tissue (%ID/g).

25 *In vivo treatment with L19-IL2 fusion protein*

Treatment with purified L19-IL2 fusion protein was performed in groups of six mice each injected subcutaneously with 20×10^6 of N592 or with 10^6 of C51 or with 3×10^6 of F9 cells. Twenty-four hours after N592, F9 and C51 cell injection, 12
30 µg of L19-IL2 fusion protein were injected into the tail vein of each animal daily for 10-15 days. Similar groups of animals (six per group) were injected with a mixture of L19 (8 µg) and recombinant human IL2 (4 µg, corresponding to 72,000 UI; Proleukin, 18×10^6 UI, Chiron) and with Phosphate

Saline Buffer pH 7.4 (PBS) for the same number of days. At the end of treatment, animals were sacrificed, tumors weighed and organs (lungs, livers, hearts, kidneys) and tumors were placed in fixative for histological analysis.

5

Microautoradiography analysis, Immunohistochemistry and Statistical analysis

Tumor and organ specimens were processed for microautoradiography to assess the pattern of ¹²⁵I-L19-IL2 fusion protein distribution within the tumors or organs as described by Tarli et al. 1999 (12). Immunohistochemical procedures were carried out as reported by Castellani et al. 1994 (11). The nonparametric Mann-Whitney test was used to assess the differences in tumor weights between the three different groups of animals (mice treated with L19-IL2 fusion protein, with mixture of L19+IL2 and PBS).

10
15

RESULTS

L19-IL2 construct and selection of clones expressing L19-IL2 fusion protein

G418 resistant clones were screened for the antibody specificity of the supernatants for the ED-B sequence by ELISA as previously described. Supernatants of clones showing immunological specificity for the ED-B sequence were tested for IL2 biological activity.

20
25

The scFv L19 and the L19-IL2 fusion protein were run on SDS-PAGE. L19-IL2 is purified in a single step by affinity chromatography, contaminations lower than 10% were detectable by SDS-PAGE. The fusion protein showed an apparent molecular mass of about 42 Kd, in line with the expected size of the fusion protein. FPLC analysis of the fusion protein on a S200 Superdex chromatography column (Pharmacia) demonstrated that

30

the protein, in native conditions, is made up of about 70% of dimers and 30% of monomers as previously observed for the scFv L19. Both the immunological activity of the scFvL19 component and the biological activity of the IL-2 component in the purified protein were tested (Figure 3). Both specific activities were comparable with purified separated molecules.

Biodistribution of radiolabeled L19-IL2 fusion protein in tumor-bearing mice

To investigate whether the L19-IL2 fusion protein was able to efficiently localize in tumoral vessels, as reported for the scFv L19 by Tarli et al. 1999 (12), biodistribution experiments were performed in F9 teratocarcinoma bearing mice.

L19-IL2 fusion protein was shown immunohistochemically to stained strongly blood vessels of glioblastoma tumor. Radioiodinated L19-IL2 fusion protein was injected in the tail vein of mice with subcutaneously implanted F9 tumors, and L19-IL2 fusion protein distribution was obtained at different time points: 3, 6 and 24 hours. Fourteen percent of the injected dose per gram of tissue (%ID/g) localized in the tumor 3 hours after injection as reported in Table 1. The localization of L19-IL2 fusion protein in the tumoral neovasculature was confirmed by microradiographic analysis.

Accumulation of the radiolabeled fusion protein was shown in the blood vessels of the F9 mouse tumor. No accumulation of radiolabeled fusion protein was detected in the vessels of the liver or of other organs of tumor bearing mice.

Treatment of tumor bearing mice with L19-IL2 fusion protein

The efficacy of the L19-IL2 fusion protein in suppressing the growth of tumors was tested on three different experimental

tumor models: mouse teratocarcinoma, F9; mouse adenocarcinoma, C51 and human small cell lung cancer, N592. For tumor induction, cells of each tumor type, (specifically 20×10^6 for N592, 10^6 for C51 and 3×10^6 for F9) were
5 injected subcutaneously in the animals. Twenty-four hours later animals began receiving daily intravenous injection of either PBS (6 animals), a mixture of L19 and IL2 (6 animals) or L19-IL2 fusion protein (6 animals) for 10-15 days. Twenty-four hours after the last injection the animals were
10 sacrificed, the tumoral mass removed and the tumors weighed.

The results, summarized in Table 2, show a significant decrease in tumor growth in the group of animals treated with L19-IL2 fusion protein with respect both to animals injected
15 with an equimolar mixture of L19 and IL2 proteins and to the third group treated with PBS.

F9 teratocarcinoma tumors were dissected from nude mice after 11 days of intravenous treatments. In L19-IL2 fusion protein
20 treatment group, the tumoral mass grew only in three out of six mice. The non parametric Mann-Whitney test was used to determine the statistical significance of differences in tumor weights between the three groups of animals. The differences in tumor weights between treatment with the
25 fusion protein (L19-IL2), treatment with PBS or a mixture (L19+IL2) were statistically significant (see Table 3).

EXAMPLE 2

CONSTRUCTION AND IN VIVO USE OF ANTIBODY-TISSUE FACTOR FUSION

30

Fusion proteins comprising antibody fragments in scFv configuration, genetically fused to truncated tissue factor (scFv-TF), were cloned and expressed. The scFv(L19) as targeting agent specific for the ED-B domain of fibronectin

was employed for targeting, and scFv(D1.3) (specific for hen egg lysozyme) as negative control.

The fusion protein scFv(L19)-TF and scFv(D1.3)-TF were expressed in *E. coli* and purified to homogeneity. The
5 antibody moiety was shown to be active by antigen binding assays. The TF moiety was shown to be active using the method of Ruf et al, *J. Biol. Chem.* 226:2158-2166. The ability of scFv (L19)-TF to target solid tumors was shown by
10 quantitative biodistribution analysis, using radioiodinated scFv (L19)-TF injected intravenously in tumor bearing mice (Figure 3).

The antitumor activity of scFv(L19)-TF and scFv(D1.3)-TF was tested in mice bearing the F9 murine teratocarcinoma, the C51
15 murine carcinoma or FE8 tumors (derived from subcutaneously implanted ras-transformed rat fibroblasts). Experiments were performed both in mice bearing small tumors and in mice bearing very large tumors.

20 scFv(L19)-TF, but not scFv(D1.3) or saline, mediated rapid and extensive tumor infarction few hours after injection.

Three injections of 20 µg scFv(L19)-TF resulted in approx. 50% reduction of growth rate in small tumors (Figures 4 and
25 5). In large tumors, one injection of 20 µg scFv(L19)-TF stopped tumor growth, by turning the majority of the tumor into a black and crusty mass (Figures 6 and 7). By contrast, one injection of 20 µg scFv(D1.3)-TF had no antitumor effect (Figures 6 and 7).

30

MATERIAL AND METHODS

Cloning of scFv(L19)-TF

The scFv(L19)-TF expression vector was constructed by cloning

a synthetic DNA sequence, coding for the human TF, at the 3' end of the DNA sequence encoding the human scFv(L19), using the NotI/EcoRI sites of a derivative of vector pDN5 (D. Neri et al. (1996) *Nature Biotechnology*, 14, 485-490.), in which
5 the scFv(D1.3) gene had been replaced by the scFv(L19) gene. The human TF DNA sequence was purchased from ATCC and modified by PCR as follows:

The primer TF-banot (5'-T GAG TCA TTC GCG GCC GCA GGT GGC GGT
10 GGC TCT GGC ACT ACA AAT ACT GTG GCA-3') introduced to the 5' end of the TF DNA sequence a restriction site for the endonuclease NotI. It also introduced a short linker C-terminally of the restriction site consistent of four glycines and a serine (GGGGS).

15 The primer TF-fostuecol (5'-GTC CTT GTA GTC AGG CCT TTC ACG GAA CTC ACC TTT CTC CTG GCC CAT ACA-3') introduced to the 3' end of the TF DNA sequence a *StuI* endonuclease restriction site and then the first four residues of the FLAG-tag. It
20 also removed a *EcoRI* restriction site in the codon for the amino acid 216 in the TF sequence by a silent mutation.

The primer TF-fostueco2 (5'-AGA GAA TTC TTA TTA CTT ATC GTC ATC GTC CTT GTA GTC AGG CCT TTC ACG-3') introduced to the
25 3' end of the product of TF-fostuecol the rest of the FLAG-tag (DYKDDDDK), a *EcoRI* restriction site and finally two stop codons.

Cloning of scFv(D1.3)-TF

30 The scFv(D1.3)-TF expression vector was constructed in a similar fashion as described above for scFv(L19)-TF. In short, the TF gene was cloned in the NotI/EcoRI sites of vector pDN5, which already contains the scFv(D1.3) gene.

Expression and purification of the scFv-TF fusion protein

The vectors were introduced in TG1 Escherichia Coli cells. Protein expression and purification by affinity chromatography were performed as described for scFv(D1.3) and
5 for scFv(L19) (Neri et al., 1996; Tarli et al. (1999) *Blood*, 94, 192-198). In addition, a purification step by ion exchange chromatography was performed, in order to obtain homogenous protein preparations.

- 10 The size of the fusion protein was analyzed in reducing conditions on SDS-PAGE and in native conditions by FPLC gel filtration on a Superdex S-75 (Amersham Pharmacia Biotech, Uppsala, Sweden).

- 15 *In vitro activity of the recombinant scFv-TF fusion protein*
The immunoreactivity of the scFv-TF fusion protein was analyzed by ELISA immunoassay, by BIAcore and by affinity chromatography on antigen column, as described (Neri et al., 1996; D. Neri et al. (1997) *Nature Biotechnology*, 15, 1271-
20 1275.; Tarli et al., 1999).

- The enzymatic activity of the scFv-TF fusion protein was analyzed using the Spectrozyme FXa assay (American Diagnostica, Pfungstadt, Germany) as described by Ruf et al
25 (1991).

In vivo targeting activity of the recombinant L19-TF fusion protein

- The in vivo targeting performance was analysed by
30 biodistribution analysis as described in Tarli et al. (1999). Briefly, purified scFv(L19)-TF fusion protein was radioiodinated and injected into nude mice with subcutaneously implanted F9 murine teratocarcinoma. Mice were sacrificed at 24 hours after injection. The organs were

weighed and the radioactivity counted. Targeting results of representative organs are expressed as percent of the injected dose per gram of tissue (%ID/g).

5 *In vivo treatment with the recombinant L19-TF fusion protein*
Tumor bearing mice were obtained by subcutaneous injection of 10^6 of FE8 rat fibroblast, C51 colon carcinoma or F9 teratocarcinoma cells (Tarli et al., 1999). The cells were allowed to grow until the tumoral volume could be measured by
10 a slide-calliper.

Mice with tumors of volume ca 200-300mm³ were injected with 20ug scFv-TF fusion protein corresponding to 10ug TF in 200ul saline. The injection was repeated after 48 and 96 hours.
15 Mice were monitored by tumor volume, weight and appearance including photographic documentation.

Mice with tumors of volume ca 1500mm³ were injected with a single dose of with 20ug scFv-TF fusion protein corresponding
20 to 10ug TF in 200ul saline. The injection was not repeated. Mice were monitored by tumor volume, weight and appearance including photographic documentation.

EXAMPLE 3

25 CONSTRUCTION AND IN VIVO USE OF ANTIBODY-DOXORUBICIN

A conjugate of the anti-FN ED-B scFv L19 and doxorubicin was constructed. As chemistry for the cleavable linker, the formation of a Schiff base (imine) between a primary amino group of the L19 antibody and the oxidised sugar moiety
30 (daunosamine) of doxorubicin was chosen.

The ability of doxorubicin to be released from scFv(L19) was assayed by HPLC. The half-life of doxorubicin release was approximately 10 hours, at pH 7.4 and 37 °C (Figure 8).

The ability of released doxorubicin to be taken up by neighboring cells (*in vitro*) and to mediate a biocidal activity was tested by cytotoxicity assays using C51 murine carcinoma cell line. Figure 9 shows that both pure
5 doxorubicin and doxorubicin released from scFv(L19)-doxorubicin have 50% inhibitory concentrations towards C51 cells in the 0.1 μ M range.

10 The anti-tumor activity of scFv(L19)-doxorubicin immunoconjugate was tested *in vivo* by repeated intravenous injections in mice bearing the subcutaneously implanted C51 murine tumor. Five injections of 18 μ g of scFv(L19)-doxorubicin caused a 50% reduction in tumor growth rate,
15 relative to control mice injected with saline (Figure 10).

MATERIALS AND METHODS

Conjugation of doxorubicin to scFv(L19)

20 The antibody fragment scFv(L19) was prepared as described in Tarli et al. (1999) *Blood*, 94, 192-198.

1 mg of doxorubicin (1.72 μ moles) was mixed with 0.53 mg (2.5 μ moles) NaIO₄ in 1 ml phosphate buffer (pH = 7.4) and
25 incubated for one hour at room temperature in the dark. 1 μ l glycerol 20% was then added in order to consume excess periodate. The solution of oxidized drug was mixed with 1.3 mg (43 nmoles) of scFv(L19) in 0.15 M potassium carbonate buffer (pH = 9.5). The formed precipitate was removed by
30 centrifugation (4000 rpm, 1') and the liquid phase was loaded onto a PD-10 disposable gel filtration column.

The molar concentrations of doxorubicin and scFv(L19) were

determined from their UV absorption at 496 and 280 nm, respectively, including a correction for the absorption of doxorubicin at 280 nm. The degree of conjugate coupling was calculated as (ScFv:doxo) molar ratio (MR) from the following

5 formula:

$$\text{MR} = \{ [A^{280} B (0.724 \times A^{496})] / [(1.4) (2.7 \times 10^4)] \} / [A^{496} / (8.03 \times 10^3)]$$

where A indicates the spectrophotometric absorbance; 0.724 is a correction for the doxorubicin absorption at 280 nm ; 2.7 x 10⁴ is the molecular weight of a scFv; 1.4 is the absorbance value at 280 nm of a solution 1mg/ml of a scFv; 8.03 x 10³ (M⁻¹ cm⁻¹) is the extinction coefficient of doxorubicin at 496 nm.

15 Coupling the L19 antibody fragment with doxorubicin previously oxidized with NaIO₄, 5 molecules of doxorubicin bound per mole of antibody fragment were obtained.

Antibody immunoreactivity after conjugation was measured by loading 200 µg of (L19-doxo) conjugate onto 200 µl of ED-B-Sepharose resin (capacity > 2 mg ED-B/ml resin) on a pasteur pipette, followed by absorbance measuring at 496 nm of the flow-through and eluate fractions. Immunoreactivity, defined as the ratio between the absorbance values of the eluted fraction and the sum of the values of the eluted and the flow-through fractions, was 30%.

Cytotoxicity test

In a 15 ml Falcon tube, a sample of scFv-doxo conjugate (2 ml) was dialyzed against PBS (4 ml) shaking at 37°C using a molecular weight cut off (MWCO) membrane of 12,000-14,000 (Socochim SA, Switzerland).

At different time intervals, the dialysis buffer was withdrawn and filtered. The amount of doxorubicin released was measured from the absorbance at 496 nm and the integration of the signal obtained by reverse phase HPLC (Figure 8). For the evaluation of the activity of the released drug, a colorimetric cytotoxicity assay in microtitration plates was used based on quantification of biomass by staining cells with Crystal Violet (Serva). Unconjugated doxorubicin and doxorubicin released from the conjugate were analyzed in parallel.

C51 murine adenocarcinoma cells were seeded in 24-well plates at a density between 10^6 and 10^7 cells per well. The plates were incubated overnight at 37°C in humidified, 5% CO_2 atmosphere to ensure the growth of the monolayer. The medium was then removed and different concentrations of doxorubicin was added. Relative cell numbers in treated and control plates were determined by crystal violet staining. Quantification is possible by solubilising the absorbed dye in ethanol 70% and determining optical density at 590 nm where absorbance is directly proportional to cell number. Relative cell number can be expressed as $T/C = (T - C_0) / (C - C_0) \times 100$ [T= absorbance of treated cultures, C= absorbance of control cultures, and C_0 = absorbance of cultures at the start of incubation ($t=0$)]. The results of this study are depicted in Figure 9.

In vivo anti-tumor activity

A set of 6 nude mice previously injected subcutaneously with C51 adenocarcinoma cells, received intravenous injections of doxo conjugated to scFv(L19) via periodate oxidation. At the same time points, a set of five mice received injection of saline buffer.

Five injections were administered to the mice each corresponding to about 18 µg of doxorubicin derivative (less than one tenth of the maximal tolerated dose for intravenously injected doxorubicin, i.e. 8 mg/kg).

5

The tumors of the mice treated with (L19-doxo) were measured regularly with a caliper and grew slower than the tumors in the untreated mice. Fourteen days after the tumor grafting, the average volume of the tumors in treated animals was about
10 half of the average volume of the tumors in non treated animals. (Figure 10).

EXAMPLE 4

Preparation of DNA construct encoding an IL12-L19 Fusion

15 *Protein and Production of the Fusion Protein*

Preparation of DNA construct

A schematic representation of the IL12-L19 cDNA construct is given in Figure 11. The gene fusion was constructed by
20 performing two rounds PCR assembly from the individual genes of the murine IL-12 subunits p35 and p40 and of scFv(L19).

The sequence of the murine IL-12 subunits p35 and p40 were obtained from ATTC (American Type Culture Collection,
25 Manassas, VA 20110, USA) and amplified by PCR with the following primers:

The primer *sp40backEco* (5' ccg gaattc atg tgt cct cag aag cta acc atc 3') anneals to the endogenous secretion sequence of
30 p40 and appends to its 5' end a restriction site for the endonuclease EcoR1.

The primer *linkp40for* (5' cc gcc acc gct ccc tcc gcc acc gga acc tcc ccc gcc gga tcg gac cct gca ggg aac 3') introduces to

the 3' end of p40 a part of the (Gly₄Ser)₃-linker to allow its PCR assembly to the 5' end of p35.

The primer *linkp35back* (5' ggc gga ggg agc ggt ggc gga ggt
5 tgc agg gtc att cca gtc tct gga cct 3') introduces to the 5'
end the complementing sequence of the (Gly₄Ser)₃-linker for
PCR assembly with p40.

The primer *linkp35for* (5' ctc acc tcc atc agc gct tcc ggc gga
10 gct cag ata gcc 3') anneals to the 3' end of p40 and appends
the sequence of a short amino acid linker (GSADGG) to connect
the p45 subunit of IL12 and L19.

The gene sequence of L19 with a FLAG tag was PCR amplified
15 with the following primers:

The primer *linkL19back* (5' gcc gga agc gct gat gga ggt gag
gtg cag ctg ttg gag tc 3') appends to 5' end of L19 the
complimentary DNA sequence of the short amino acid linker
20 (GSADGG) between p35 and L19.

The primer *FlagforNot* (5' a agg aaa aaa gcgccgc cta ttt gtc
atc atc gtc ttt gta gtc 3') anneals to the Flag sequence of
L19Flag and introduces a stop codon as well as a restriction
25 site for the endonuclease NotI at the 3' end.

Nucleic acid encoding IL12-L19 was constructed by performing
two rounds of PCR assembly. First, the p40 and p35 fragments
were fused by PCR assembly, using primers *sp40backEco* and
30 *linkp35for*. In a second PCR assembly step with the primers
sp40backEco and *FlagforNot*, the DNA fragment encoding p40-
linkers-p35 was fused to the 5' end of L19. The assembled
IL12-L19 was cloned into the mammalian cell expression vector
pcDNA3.1 (+) vector (Invitrogen, Groningen, The Netherlands),

using the EcoR1/Not1 sites of the vector.

Expression and Purification of IL12-L19

5 HEK 293 cells (Human embryonic kidney cells) were transfected with the vector and stable transfectants selected in the presence of G418 (500µg/ml). Clones of G418-resistant cells were screened for IL12 expression by ELISA using recombinant ED-B domain of Human fibronectin as antigen.

10 The IL12-L19 fusion protein was purified from cell culture medium by affinity chromatography over ED-B conjugated to Sepharose. The size of the fusion protein was analysed in reducing conditions on SDS-PAGE and in native conditions by FPLC gel filtration on a Superdex S-200 (Amersham
15 Pharmaceutica Biotech, Uppsala, Sweden).

Determination of IL 12 Bioactivity

The IL12 activity of the IL12-L19 fusion protein was determined by performing a T cell proliferation assay (Gately et al., Current Protocols in Immunology, 1997). Resting
5 human peripheral blood monocytes (PBMC) were cultured with mitogen (phytohemagglutinin and IL-2) for 3 days and then incubated with serial dilutions of either fusion protein or commercially available, recombinant, murine IL12 standard. Proliferation was subsequently measured by [³H]thymidine
10 incorporation (Figure 12).

*EXAMPLE 5**In Vivo Treatment with IL12-L19 Fusion Protein*

15 *In vivo* targeting activity was analysed by performing biodistribution experiments with radioiodinated fusion protein in nude mice (RCC Füllinsdorf) bearing subcutaneously grafted F9 murine teratocarcinoma (Tarli et al., 1999). Biodistribution data were obtained from mice sacrificed at 1,
20 4 and 24 hours after injection. At these time points, the tumor, the organs and the blood were removed, weighed and radioactivity counted. Targeting results were expressed as a percent injected dose per gram of tissue (%ID/g). The results are shown in Figure 13.

25

BALB/c mice (RCC Füllinsdorf) were injected subcutaneously with 5×10^6 cells of C51 colon carcinoma. Two therapy experiments, with five or six animals per group each, were performed on either small or large tumor bearing mice.

30

In the first case, therapy was started four days after tumor cell injection, when small tumors were clearly visible ($\approx 30\text{mm}^3$). In the treated group, mice were injected into the tail vein with 2.5 μg of IL12-L19 fusion protein every 48

hours. The control group received PBS injections according to the same schedule. At the end of the treatment, animals were sacrificed, tumors were weighed and organs and tumors were placed in fixative for histological analysis.

5

The results are shown in Figure 14.

In a second experiment, therapy was started when the average tumor volume had reached 300mm³. Mice of the treated group were subsequently injected intravenously with 10µg of IL12-L19 fusion protein every 48 hours, with the control group receiving PBS injections, respectively.

10

The results are shown in Figure 15.

15

EXAMPLE 6

ScFv(L19)-interferon-γ

The present inventors have found that when targeting the L19-interleukin-12 fusion protein to tumor vasculature in tumor bearing mice, they have observed increased levels of IFN-γ in the blood. In contrast, no elevated levels of IFN-γ could be detected with a non-targeted scFv-interleukin-12 fusion protein.

20

The inventors have investigated two avenues for fusing IFN-γ to scFv (such as L19). Previously, there has been a difficulty represented by the fact that IFN-γ needs to be homodimeric in order to be biologically active. A fusion protein between IFN-γ and (either the heavy chain or the light chain of) an IgG (which is, in turn, a homodimeric molecule), would result in the non-covalent polymerisation/precipitation of the resulting fusion protein.

25

30

In the first approach (Figure 17), IFN- γ monomer was fused at the C-terminal extremity of scFv. The resulting fusion protein was well expressed in stably-transfected mammalian cell culture, yielding a pure protein (after affinity chromatography on ED-B resin), with an apparent molecular weight of 43 kDalton in reducing SDS-PAGE. The protein was mainly homodimeric in solution, as determined by gel-filtration chromatography using a Superdex-200 column (Amersham-Pharmacia, Dübendorf, Zürich, Switzerland). Both the scFv and the IFN- γ moieties were shown to be active in the fusion protein, since scFv(actually L19)-IFN- γ was able to bind with high-affinity to the ED-B domain of fibronectin and to block the proliferation of tumor cells, in a typical IFN- γ -dependent fashion.

In the second approach (Figure 18), IFN- γ homodimer (consisting of two IFN- γ joined together by a polypeptide linker) was fused at the C-terminal extremity of scFv(L19). The resulting fusion protein was well expressed in stably-transfected mammalian cell culture, yielding a pure protein (after affinity chromatography on ED-B resin), with an apparent molecular weight of 59 kDalton in reducing SDS-PAGE. The protein was mainly homodimeric in solution, as determined by gel-filtration chromatography using a Superdex-200 column (Amersham-Pharmacia, Dübendorf, Zürich, Switzerland). The nature of the fusion protein in solution, with four antigen-binding sites and four IFN- γ monomeric units, is compatible with biological activity. The fusion protein showed strong binding to the ED-B domain of fibronectin both by ELISA and by BIAcore analysis, and it was able to block the proliferation of tumor cells, in a typical IFN- γ -dependent fashion.

The anti-tumor activities of scFv(L19)- IFN- γ and scFv(L19)-(IFN- γ)₂ are demonstrated in tumor-bearing mice.

5 Experimental procedures

Primer sequences are shown in Table 4.

10 Cloning of L19-IFN- γ into the pcDNA3.1(+) vector: plasmid pIS14.

Murine IFN- γ coding sequence (purchased from ATCC, Manassas, VA 20110, USA, ATCC No. 63170) was amplified using primers 6 and 5. In a second PCR reaction, a peptidic Flag tag was
15 appended at the C-terminus of the fusion protein using primers 6 and 2.

The resulting insert was purified, digested with Sac II/ Not I and ligated in a Sac II/ Not I double digested modified
20 pcDNA3.1(+) vector. The vector had previously been modified as follows: An IgG secretion sequence was fused N-terminally to the scFv (L19) and the construct was cloned HindIII/Eco RI into the pcDNA3.1(+) vector. C-terminal of the scFv (L19) is a short 5 amino acid linker encoded by TCC GGA TCC GCG GGA.
25 See Figure 19.

Cloning of L19-(IFN- γ)₂ into the pcDNA3.1(+)vector: plasmid pIS16.

30 The murine IFN- γ dimer was cloned by ligating two separately amplified IFN- γ monomers. One IFN- γ monomer was amplified using primers 6 and 8, thus appending a Sac II restriction site to the 5' end, and a 10 amino acid linker encoded by GGC

GAT GGG GGA ATT CTT GGT TCA TCC GGA containing an internal EcoR I restriction site to the 3' end. See Figure 18. The second IFN- γ monomer was amplified with primers 7 and 5, followed by a second PCR reaction, using primers 7 and 2, thus adding the 10 amino acid linker containing an internal EcoR I restriction site to the 5' end, and a peptidic Flag-tag followed by a Not I restriction site to the 3' end. The two fragments corresponding to monomeric subunits of IFN- γ were digested with EcoRI and ligated. The band corresponding to the ligation product was gelpurified on an agarose gel, digested with Sac II/ Not I and ligated into the Sac II/ Not I double digested modified pcDNA3.1(+) vector. The vector had previously been modified as follows: An IgG secretion sequence was fused N-terminally to the scFv (L19) and the construct was cloned HindIII/Eco RI into the pcDNA3.1(+) vector. C-terminal of the scFv (L19) is a short 5 amino acid linker (see Figure 20).

Expression and purification of L19-IFN- γ and L19-(IFN- γ)₂
HEK 293 cells (human embryonic kidney cells) were transfected with the vector pIS 14 and pIS 16 and stable transfectants selected in the presence of G418 (500 μ g/ml) using standard protocols (Invitrogen, Groningen, The Netherlands). Clones of G418-resistant cells were screened for IFN- γ expression by ELISA using recombinant ED-B domain of human fibronectin as antigen. The L19-IFN- γ and L19-(IFN- γ)₂ fusion proteins were purified from cell culture medium by affinity chromatography over a ED-B conjugated CM Sepharose column. The size of the fusion protein was analyzed in reducing conditions on SDS-PAGE and in native conditions by FPLC gel filtration on a Superdex S-200 column (Amersham Pharmacia Biotech, Uppsala, Sweden).

EXAMPLE 7

Construction and in vivo anti-tumor activity of antibody

5 *mTNF α fusion.*

Materials and Methods

Construction and expression of L19-mTNF α fusion protein.

10 The L19-mTNF α cDNA was constructed by fusion of a synthetic sequence coding for mouse TNF α (Pennica et al., *Proc. Natl. Acad. Sci USA*, 82: 6060-6064, 1985) to the 3' end of the sequence coding for the scFV L19. The schematic representation of L19-mTNF α cDNA construct is shown in Figure
15 21. TNF α cDNA was amplified by Polymerase Chain Reaction (PCR) using BC742 and BC749 primers and, as template the m-TNF α cDNA produced by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) starting from RNA obtained from the spleen of immunized mice.

20

The forward primer (BC742) for mouse TNF α (sequence: 5'CTCGAATTCTCTTCCTCATCGGGTAGTAGCTCTTCCGGCTCATCGTCCAGCGGCCTCAG ATCATCTTCTCAAAT3') contained the EcoRI restriction enzyme sequence, a 45 bp encoding for a 15 amino acids linker (Ser₄ -
25 Gly)₃ and 21 bases of the mature mouse TNF α sequence (Pennica et al., 1985).

The reverse BC-749 primer (sequence 5'CTCGCGCCGCTCATCACAGAGCAATGACTCCAAAGTA3') contained 21
30 bases of the mature mouse TNF α (Pennica et al., 1985, two stop codons and the Not I restriction enzyme sequence.

The scFv L19, which contained in its 5' end the genomic sequence of the signal secretion peptide as reported by Li et

al (*Protein Engineering*, 10:731, 1996 or 1997), was amplified by PCR using T7 primer on the vector pcDNA3.1 (Invitrogen, Croningen, The Netherlands) and the BC 679 primer (sequence: CTCGAATTCTtttgatttccaccttggtccc) containing 21bp of the 3' end of L19 and the EcoRI restriction enzyme sequence.

The fused gene was sequenced, introduced into the vector pcDNA3.1 containing the Cytomegalovirus (CMV) promoter and expressed in p3U1 cells in the presence of G418 (750 µg/ml, Calbiochem, San Diego, CA). Clones of G418-resistant cells were screened for the secretion of L19-mTNFα fusion protein by ELISA using recombinant ED-B domain of human Fibronectin (FN) as antigen for L19 and rabbit anti-murine TNFα polyclonal antibody (PeproTech, UK) as specific reagent for immunoreactive mTNFα.

FN recombinant fragments, ELISA immunoassay and purification of fusion protein L19-mTNFα

Recombinant ED-B FN fragment was produced as described by Carnemolla et al (*Int. J. Cancer*, 68:397, 1996). ELISA immunoassay was performed as reported by Carnemolla et al (1996). The L19-m TNFα fusion protein was purified from the conditioned medium of one positive clone using the recombinant human fibronectin fragment ED-B conjugated to Sepharose, by affinity chromatography, as reported by Carnemolla et al (1996). The size of the fusion protein was analysed in reducing conditions on SDS-PAGE and in native conditions by FPLC on a Superdex S-200 chromatography column (Amersham Pharmacia Biotech, Uppsala, Sweden).

30

L-M cytotoxicity assay

The mTNFα biologic activity of the L19-mTNFα fusion protein was determined by the cytotoxicity assay using mouse L-M fibroblasts as described by Corti et al (*J. Immunol. Methods*,

177: 191-194, 1994). Serial dilutions of L19-mTNF α fusion protein and of recombinant mTNF α (2×10^7 units/mg) at concentrations from 1000 to 0.4 pg/ml were used in the cytotoxic assay. Results are expressed as a percent of
5 viable cells with respect to negative controls.

Animal and cell lines

Male and female 129 and Balb-C mice (8 week-old) were obtained from Harlan Italy (Correzzana, Milano, Italy). F9,
10 a mouse embryonal carcinoma, mouse L-M fibroblasts and p3U1 mouse myeloma cells were purchased from ATCC (American Type Culture Collection, Rockville, MD, USA); C51, a mouse colon adenocarcinoma cell line derived from Balb/C, was used (Colombo et al., *Cancer Metastasis Rev.*, 16:421-432, 1997).

15

Biodistribution of L19-mTNF α fusion protein

Purified L19-mTNF α was radiolabeled with iodine-¹²⁵ using the Iodogen method (Salacinski et al., *Anal. Biochem.*, 117: 136, 1981) (Pierce, Rockford, IL). After labelling, the
20 immunoreactivity was more than 90%. 129 mice with subcutaneously implanted F9 murine teratocarcinoma were intravenously injected with 4 μ g (2 μ Ci) of protein in 100 μ l saline solution. Three animals were used for each time point. Mice were sacrificed at 3, 6, 24 and 48 hours after
25 injection. The organs were weighed and the radioactivity was counted. All organs and tumors were placed in fixative for histological analysis and microautoradiography. Targeting results of representative organs are expressed as percent of the injected dose per gram of tissue (%ID/g).

30

In vivo treatment with L19 mTNF α fusion protein

Treatment with purified L19-mTNF α fusion protein was preformed in groups of 3 Balb.C mice each injected subcutaneously with 10^6 of C51 cells. At day 12 after C51

cell injection, 0.8µg/g of L19-TNFα fusion protein was injected into the tail vein of each animal. A similar group of 3 animals was injected with Phosphate Saline Buffer, pH 7.4 (PBS). The animals were followed for systemic toxicity (weight loss) and tumor growth daily for 6 days. At the end, animals were sacrificed and tumors were placed in fixative for histological analysis and snap frozen for immunohistochemical analysis.

10 Microautoradiography analysis and Immunohistochemistry

Tumor and organ specimens were processed for microautoradiography to assess the pattern of ¹²⁵I-L19TNFα fusion protein distribution within the tumors or organs as described by Tarli et al (*Blood*, 94: 192-198, 1999).
15 Immunohistochemical procedures were carried out as reported by Castellani et al (*Int. J. Cancer*, 59: 612-618, 1994).

Results

20 L19-mTNFα construct and selection of clones expressing L19-mTNFα fusion protein G418 resistant clones were screened for the antibody specificity of the supernatants for the ED-B sequence and for immunoreactive mTNFα by ELISA, as described in Materials and Methods.

25 Supernatants of clones showing immunological specificity for the ED-B sequence and immunoreactive mTNFα were tested for the TNFα biological activity in the L-M cytotoxicity assay (see Materials and Methods).

30

L19-mTNFα fusion protein was purified in a two step procedure:

- a) by immunoaffinity chromatography, on ED-B sepharose column followed by

- b) size exclusion chromatography (Superdex 200,
Pharmacia)

In SDS-PAGE, the fusion protein showed an apparent molecular
5 mass of about 42 kDa, as expected. Both the immunological
activity of the scFv L19 component and the biological
activity of the mTNF α component in the purified protein were
tested.

10 *Biodistribution of radiolabeled L19-mTNF α fusion protein in
tumor-bearing mice*

To investigate whether the L19-mTNF α fusion protein was able
to efficiently localise in tumoral vessels, as reported for
scFv L19 by Tarli et al (*Blood*, 94: 192-198, 1999),
15 biodistribution experiments were performed in F9
teratocarcinoma-bearing mice.

L19-mTNF α fusion protein was shown immunohistochemically to
strongly stain blood vessels of glioblastoma tumor.
20 Radioiodinated L19-mTNF α fusion protein was injected in the
tail vein of mice with subcutaneously implanted F9 tumors,
and L19-TNF α fusion protein distribution was obtained at
different time points: 3, 6, 24 and 48 hours. As reported in
Table I, 22% of the injected dose per gram of tissue (%ID/g)
25 localised in the tumor 3 hours after injection and after 48
hours more than 9% ID/g was still in the tumor. The
localisation of L19-mTNF α fusion protein in the tumoral
neovasculature was confirmed by microradiographic analysis.
Accumulation of the radiolabeled fusion protein was shown in
30 the blood vessels of the F9 mouse tumor. No accumulation of
radiolabeled fusion protein was detected in the vessels of
the other organs of tumor bearing mice.

Treatment of tumor bearing mice with L19-mTNF α fusion protein

The efficacy of the L19-mTNF α fusion protein in suppressing tumor growth was tested on one experimental tumor model of mouse adenocarcinoma, C51. For tumor induction, 10⁶ C51 cells
5 were injected subcutaneously in Balb/C animals. After 12 days (when the tumor reaches approximately 100-200mm³) animals received intravenous injections of either PBS (3 animals) or L19-mTNF α fusion protein (3 animals). The animals were monitored for weight and tumor growth daily for 6 days. The
10 results, summarised in Figure 23, show a decrease in tumor growth in the group of animals treated with L19-mTNF α fusion protein with respect to animals injected with PBS (bars represent SE). The weight loss was always less than 6% throughout the experiment time.

15

REFERENCES

- 1) Folkman Nat. Med. 1: 27, 1995.
- 2) O'Reilly et al. Nat. Med. 2: 689, 1996.
- 3) O'Reilly et al. Cell, 88, 277, 1997.
- 20 4) Friedlander et al. Science, 270: 1500, 1995.
- 5) Pasqualini et al. Nat. Biotechnol. 15: 542, 1997.
- 6) Huang et al. Science, 275: 547, 1997.
- 7) Kim et al. Nature, 362: 841, 1993.
- 8) Schmidt-Erfurth et al. Br. J. Cancer, 75: 54, 1997.
- 25 9) Zardi et al. EMBO J., 6, 2337-2342 (1987).
- 10) Carnemolla et al. J. Cell Biol., 108, 1139-1148 (1989).
- 11) Castellani et al. Int.J.Cancer, 59, 612-618 (1994).
- 12) Tarli et al. Blood, 94: 192-198, 1999.
- 13) Viti et al. Cancer Res. 59: 347, 1999.
- 30 14) Taniguchi et al. Cell 73:5-8, 1993.
- 15) Rosenberg J. Clin. Oncol. 10:180-199, 1992.
- 16) Siegel and Puri Interleukin-2 toxicity. J. Clin. Oncol. 9:694-704, 1991.
- 17) Lode et al. Pharmacol. Ther. 80:277-292, 1998.

- 18) Meazza et al. Br. J. Cancer, 74: 788-795, 1996.
- 19) Li et al. Protein Engineering, 10: 731, 1997.
- 20) Carnemolla et al. Int. J. Cancer 68:397, 1996.
- 21) Colombo et al. Cancer Metastasis Rev. 16:421-432, 1997.
- s 22) Salacinski et al. Anal. Biochem. 117:136, 1981.
- 23) Neri et al. Nat. Biotechnol. 15:1271, 1997.

Table 1. Biodistribution of Radiolabeled L19-IL2 fusion protein in Tumor-Bearing Mice

%ID/g Time (h)	Tumour	Blood	Skin	Liver	Spleen	Kidney	Bladder	Thyroid	Heart	Lung	Muscle
3	14.01±2.12	6.97±1.14	2.73±0.59	2.61±0.41	3.90±0.97	4.69±0.53	2.16±1.42	5.13±0.60	2.27±0.45	10.32±1.83	1.34±0.75
6	8.96±1.41	2.65±0.73	1.48±0.57	1.23±0.19	2.05±0.41	1.98±0.34	6.28±3.98	4.98±2.99	1.22±0.34	5.40±0.61	0.53±0.24
24	4.06±1.06	0.14±0.04	0.58±0.43	0.13±0.05	0.16±0.05	0.19±0.08	0.83±0.51	0.22±0.12	0.09±0.04	0.48±0.27	0.05±0.02

Biodistribution studies were performed as described in Materials and Methods.

Abbreviation: %ID/g, percent of L19-IL2 fusion protein injected dose per gram of tissue.

Table 2. Effect on tumor growth of L19-IL2 fusion protein

Tumor cells	L19-IL2 fusion protein*	L19+IL2	PBS
C51	0.017±0.02 ¹	0.228±0.14	0.410±0.17
N592	0.173±0.17	0.705±0.32	1.178±0.75
F9	0.061±0.10 ²	0.665±0.40	1.715±0.57

Values reported represent the mean tumor weight (g) ± sdev, groups of six mice for each experiment were used.

1: A tumoral mass grew only in 4 mice out 6.

2: A tumoral mass grew only in 3 mice out 6.

* : Differences in tumor weights between fusion protein (L19-IL2) treatment and PBS or mixture (L19+IL2) control groups were statistically significant ($P < 0.01$)

Table 3. Statistical comparison (*P* values) between the different treatment groups in three tumor types.

Groups compared	Tumor types		
	F9	N592	C51
L19-IL2 fusion protein/ PBS	0.002	0.004	0.002
L19-IL2 fusion protein/ Mixture (L19+IL2)	0.004	0.009	0.002
Mixture (L19+IL2)/ PBS	0.004	0.093	0.093

TABLE 4

PRIMER SEQUENCES

5 2) **flagfoNotPicz2**

5'-ACT CAG TAA GGC GGC CGC CTA TTA CTT ATC GTC ATC GTC CTT
GTA GTC-3'

3) **XbaIL19fo**

10 5'- TCC GTC TAG ATC AGC GCT GCC TTT GAT TTC CAC CTT GGT CCC
TTG-3'

4) **IfnXbaba**

5'-GGC AGC GCT GAT CTA GAC GGA TGT TAC TGC CAC GGC ACA GTC
15 ATT GAA AGC -3'

5) **Ifnflagfol**

5'-ATC GTC ATC GTC CTT GTA GTC GCA GCG ACT CCT TTT CCG CTT -
3'
20

6) **IFNBamba**

5' AAA TCC GGA TCC GCG GGA TGT TAC TGC CAC GGC ACA GTC

7) **IFNEcoba**

25 5' GAT GGG GGA ATT CTT GGT TCA TCC GGA TGT TAC TGC CAC GGC
ACA GTC ATT GAA 3'

8) **IFNEcofo**

5' GGA TGA ACC AAG AAT TCC CCC ATC GCC GCA GCG ACT CCT TTT
30 CCG CTT 3'

9) **SeqPicback**

5' G CCA TTT TCC AAC AGC ACA AAT AAC GGG TT 3'

10) SeqPicfor

5' G ATG ATG GTC GAC GGC GCT ATT CAG 3'

Table 5 Biodistribution of radiolabeled L19-TNF α fusion protein in tumor-bearing mice

$\frac{\%ID}{g}$ Time(h)	Tumor	Blood	Skin	Liver	Spleen	Kidney	Bladder	Thyroid	Heart	Lung	Muscle
3	22,02 \pm 2,3	8,39 \pm 5,0	2,83 \pm 1,3	8,42 \pm 1,9	9,08 \pm 2,0	7,96 \pm 3,0	37,52 \pm 26,7	3,21 \pm 0,8	2,69 \pm 0,7	6,56 \pm 1,7	1,33 \pm 0,3
6	11,57 \pm 2,7	2,13 \pm 0,9	1,68 \pm 0,9	2,39 \pm 0,9	3,29 \pm 0,9	6,06 \pm 5,2	18,14 \pm 9,1	2,91 \pm 1,8	1,32 \pm 0,5	2,79 \pm 1,4	0,76 \pm 0,2
24	9,77 \pm 1,4	0,09 \pm 0,0	0,03 \pm 0,0	0,15 \pm 0,0	0,13 \pm 0,0	0,18 \pm 0,0	2,9 \pm 2,2	1,93 \pm 0,5	0,06 \pm 0,0	0,18 \pm 0,1	0,05 \pm 0,0
48	9,55 \pm 1,7	0,01 \pm 0,0	0,01 \pm 0,0	0,02 \pm 0,0	0,01 \pm 0,0	0,05 \pm 0,0	0,08 \pm 0,0	0,0 \pm 0,0	0,01 \pm 0,0	0,02 \pm 0,0	0,0 \pm 0,0

63

Biodistribution studies were performed as described in Materials and Methods
 Abbreviation: %ID/g, percent of L19-TNF α fusion protein injected dose per gram of tissue

CLAIMS:

1. A conjugate of (i) a specific binding member specific for an extracellular matrix component which is present in angiogenesis in pathological lesions, and (ii) a molecule selected from the group consisting of: interleukin-2 (IL-2), interleukin-12 (IL-12), Tumor Necrosis Factor α (TNF α), Interferon- γ (IFN- γ), Tissue Factor protein and doxorubicin, with the proviso that where said molecule is Tissue Factor protein the specific binding member comprises one or more VH and/or VL domains of antibody L19 and/or competes with antibody L19 for binding to fibronectin ED-B, the amino acid sequences of the VH and VL domains of antibody L19 being disclosed in Pini et al. (1998) *J. Biol. Chem.* 273: 21769-21776.
2. A conjugate according to claim 1 wherein said specific binding member is specific for an extracellular matrix component which is present in angiogenesis in tumors.
3. A conjugate according to claim 2 wherein said extracellular matrix component is fibronectin ED-B.
4. A conjugate of (i) a specific binding member specific for an extracellular matrix component which is present in angiogenesis in pathological lesions, and (ii) a molecule which exerts a biocidal or cytotoxic effect on target cells by cellular interaction, characterised in that the specific binding member comprises one or more VH and/or VL domains of antibody L19 and/or competes with antibody L19 for binding to fibronectin ED-B, the amino acid sequences of the VH and VL domains of antibody L19 being disclosed in Pini et al. (1998) *J. Biol. Chem.* 273: 21769-21776.

5. A conjugate according to claim 4 wherein said molecule is selected from the group consisting of interleukin-2 (IL-2), interleukin-12 (IL-12), Tumor Necrosis Factor α (TNF α),
5 Interferon- γ (IFN- γ), Tissue Factor protein and doxorubicin.

6. A conjugate according to any one of claims 1 to 5 wherein the specific binding member is a single-chain.

10 7. A conjugate according to claim 6 which comprises a fusion protein of (a) said specific binding member and (b) said molecule or a polypeptide chain of said molecule that associates with a second polypeptide chain of said molecule.

15 8. A conjugate according claim any one of claims 1 to 5 wherein the specific binding member is multi-chain.

9. A conjugate according to claim 8 which comprises (a) a fusion protein of a first chain of the specific binding
20 member and a chain of the molecule and (b) a fusion protein of a second chain of the specific binding member and a chain of the molecule.

10. A conjugate according to any one of claims 1 to 9 for
25 use in a method of treatment of the human or animal body by therapy.

11. A conjugate according to claim 10 for use in a method of treatment of angiogenesis in pathological lesions.

30

12. A conjugate according to claim 11 for use in a method of treatment of a tumor.

13. Use of a conjugate according to any one of claims 1 to 9 in the manufacture of a medicament for treatment of angiogenesis in pathological lesions.
- 5 14. Use according to claim 13 wherein said medicament is for treatment of a tumor.
15. A method of treating angiogenesis in pathological lesions, the method comprising administering a conjugate
10 according to any one of claims 1 to 9.
16. A method according to claim 15 comprising treating a tumor.




Figure 1




Figure 2

3/21




Figure 3

4/21




Figure 4

5/21




Figure 5

6/21




Figure 6




Figure 7




Figure 8

9/21




Figure 9

10/21




Figure 10

11/21




Figure 11

12/21




Figure 12




Figure 13

14/21




Figure 14

15/21




Figure 15

16/21




Figure 16

17/21




Figure 17




Figure 18

18/21




Figure 19




Figure 20

19/21




Figure 21

20/21




Figure 22

21/21




Figure 23

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62298 A3

(51) International Patent Classification?: **A61K 47/48,**
C07K 14/525, 14/54, 14/57, A61P 35/00

(21) International Application Number: PCT/IB01/00382

(22) International Filing Date: 22 February 2001 (22.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/184,767 24 February 2000 (24.02.2000) US
60/257,192 21 December 2000 (21.12.2000) US

(71) Applicant (for all designated States except US): **PHILO-**
GEN S.R.L. [IT/IT]; La Lizza-7, I-53100 Siena (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZARDI, Luciano**
[IT/IT]; IST-Istituto Nazionale per la Ricerca sul Cancro,
Largo Rosanna Benzi, 10, I-16132 Genoa (IT). **NERI,**
Dario [IT/CH]; Department of Applied Biosciences,
Swiss Federal Institute of Technology Zurich, Irchel Y36
M14, Winterthurerstrasse 190, CH-8057 Zurich (CH).
CARNEMOLLA, Barbara [IT/IT]; Via Umberto Ter-
racini, 134/2, I-16166 Genoa (IT). **NILSSON, Fredrik**
[CH/CH]; Department of Applied Biosciences, Swiss
Federal Institute of Technology Zurich, Irchel Y36 M14,
Winterthurerstrasse 190, CH-8057 Zurich (CH). **TARLI,**
Lorenzo [IT/CH]; Department of Applied Biosciences,
Swiss Federal Institute of Technology Zurich, Irchel
Y36 M14, Winterthurerstrasse 190, CH-8057 Zurich

(CH). **BORSI, Laura** [IT/IT]; Via Eugenia Ravasco, 4/2,
I-16128 Genoa (IT). **HALIN, Cornelia** [CH/CH]; Depart-
ment of Applied Biosciences, Swiss Federal Institute of
Technology Zurich, Irchel Y36 M14, Winterthurerstrasse
190, CH-8057 Zurich (CH).

(74) Agents: **WALTON, Seán, M.** et al.; Mewburn Ellis, York
House, 23 Kingsway, London, Greater London WC2B 6HP
(GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
20 June 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/62298 A3

(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS IN PATHOLOGICAL LESIONS

(57) Abstract: Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12(IL-12), Interferon- γ (IFN- γ), Tumor Necrosis Factor α (TNF α) or Tissue Factor protein (which may be truncated).

INTERNATIONAL SEARCH REPORT

International Application No

PC1/IB 01/00382

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/48 C07K14/525 C07K14/54 C07K14/57 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 01 61017 A (FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR) 23 August 2001 (2001-08-23) claims 1-16 page 6, line 13 - line 18 ---	1-3,6-16
X	WO 96 01653 A (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ET AL) 25 January 1996 (1996-01-25) claims 1-172 --- -/--	1,2,6-16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

23 January 2002

Date of mailing of the international search report

31/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

International Application No

PC1/IB 01/00382

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EPSTEIN A L ET AL: "IDENTIFICATION OF A MONOCLONAL ANTIBODY, TV-1, DIRECTED AGAINST THE BASEMENT MEMBRANE OF TUMOR VESSELS, AND ITS USE TO ENHANCE THE DELIVERY OF MACROMOLECULES TO TUMORS AFTER CONJUGATION WITH INTERLEUKIN 2 1" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 12, 15 June 1995 (1995-06-15), pages 2673-2680, XP002069098 ISSN: 0008-5472 abstract page 2677, left-hand column -page 2679, left-hand column</p> <p>---</p>	1,2,6-16
Y	<p>WO 99 58570 A (EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH) 18 November 1999 (1999-11-18) claims 1-27</p> <p>---</p>	1-16
Y	<p>US 5 650 150 A (S. D. GILLIES) 22 July 1997 (1997-07-22) claims 1-21</p> <p>---</p>	1-16
A	<p>WO 97 45544 A (MEDICAL RESEARCH COUNCIL ET AL) 4 December 1997 (1997-12-04) claims 1-29</p> <p>---</p>	1-16
A	<p>VITI F ET AL: "Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 2, 15 January 1999 (1999-01-15), pages 347-352, XP002124782 ISSN: 0008-5472 cited in the application the whole document</p> <p>---</p>	1-16
A	<p>NERI ET AL: "Affinity reagents against tumour-associated extracellular molecules and new forming vessels" ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 31, no. 1/2, 6 April 1998 (1998-04-06), pages 43-52, XP002124780 ISSN: 0169-409X the whole document</p> <p>---</p>	1-16
	<p>---</p> <p>---/---</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PC1/IB 01/00382

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NERI D ET AL: "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform"</p> <p>NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US,</p> <p>vol. 15, no. 12, November 1997 (1997-11), pages 1271-1275, XP002124779</p> <p>ISSN: 1087-0156</p> <p>cited in the application</p> <p>page 1273, right-hand column -page 1274, left-hand column, line 5</p>	1-16
A	<p>CARNEMOLLA B ET AL: "PHAGE ANTIBODIES WITH PAN-SPECIES RECOGNITION OF THE ONCOFOETAL ANGIOGENESIS MARKER FIBRONECTIN ED-B DOMAIN"</p> <p>INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US,</p> <p>vol. 68, no. 3,</p> <p>4 November 1996 (1996-11-04), pages 397-405, XP002042102</p> <p>ISSN: 0020-7136</p> <p>cited in the application</p> <p>abstract</p>	1-16
A	<p>PINI A ET AL: "Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US,</p> <p>vol. 273, no. 34,</p> <p>21 August 1998 (1998-08-21), pages 21769-21776, XP002124781</p> <p>ISSN: 0021-9258</p> <p>cited in the application</p> <p>abstract</p>	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 01/00382

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0161017	A	23-08-2001	AU 4413501 A WO 0161017 A2	27-08-2001 23-08-2001
WO 9601653	A	25-01-1996	AT 198712 T AU 702250 B2 AU 2824995 A BR 9508402 A CA 2194369 A1 DE 69519929 D1 DE 69519929 T2 DK 771216 T3 EP 0771216 A1 ES 2153483 T3 HU 76970 A2 JP 10505327 T NZ 288883 A PT 771216 T WO 9601653 A1 US 6036955 A US 5877289 A US 6093399 A US 6004555 A	15-02-2001 18-02-1999 09-02-1996 21-10-1997 25-01-1996 22-02-2001 23-05-2001 05-02-2001 07-05-1997 01-03-2001 28-01-1998 26-05-1998 23-12-1998 31-07-2001 25-01-1996 14-03-2000 02-03-1999 25-07-2000 21-12-1999
WO 9958570	A	18-11-1999	AU 4039899 A BG 105030 A BR 9910394 A CN 1303393 T WO 9958570 A2 EP 1084145 A2 HU 0102992 A2 NO 20005694 A SK 16792000 A3	29-11-1999 28-09-2001 09-01-2001 11-07-2001 18-11-1999 21-03-2001 28-11-2001 10-01-2001 10-05-2001
US 5650150	A	22-07-1997	AU 660297 B2 AU 9059691 A CA 2095836 A1 EP 1149913 A1 EP 0574395 A1 JP 9506761 T JP 2001095566 A WO 9208495 A1	22-06-1995 11-06-1992 10-05-1992 31-10-2001 22-12-1993 08-07-1997 10-04-2001 29-05-1992
WO 9745544	A	04-12-1997	AU 729081 B2 AU 2910197 A BG 102950 A BR 9709350 A CA 2256308 A1 CN 1219968 A CZ 9803815 A3 EP 0906426 A1 WO 9745544 A1 JP 2000511416 T NO 985459 A PL 330075 A1 SK 161298 A3 TR 9802416 T2	25-01-2001 05-01-1998 31-08-1999 04-01-2000 04-12-1997 16-06-1999 17-03-1999 07-04-1999 04-12-1997 05-09-2000 22-01-1999 26-04-1999 12-07-1999 22-02-1999